Stock SYNGENE SYNGENE INTERNATIONAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Syngene International Limited

Equities

SYNGENE

INE398R01022

Biotechnology & Medical Research

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-04-26 am EDT 		5-day change 1st Jan Change
698.6 INR -0.07% Intraday chart for Syngene International Limited -2.14% -0.41%
Apr. 26 Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690 MT
Apr. 25 Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 95,081 215,498 236,970 236,120 277,831 - -
Enterprise Value (EV) 1 95,081 213,001 234,369 228,312 269,685 268,728 264,121
P/E ratio 23.2 x 53.8 x 60.9 x 51.7 x 55.4 x 50.9 x 39.9 x
Yield - - 0.08% 0.08% 0.19% 0.18% 0.22%
Capitalization / Revenue 4.73 x 9.87 x 9.1 x 7.4 x 8 x 7.06 x 6 x
EV / Revenue 4.73 x 9.75 x 9 x 7.15 x 7.73 x 6.83 x 5.7 x
EV / EBITDA 15.4 x 32.5 x 29.4 x 24.4 x 25.2 x 23 x 18.6 x
EV / FCF - 81.8 x 223 x 74.8 x 49 x 130 x 76.8 x
FCF Yield - 1.22% 0.45% 1.34% 2.04% 0.77% 1.3%
Price to Book 4.41 x 7.7 x 7.26 x 6.6 x 6.9 x 5.87 x 5.21 x
Nbr of stocks (in thousands) 395,924 396,537 396,537 397,175 397,697 - -
Reference price 2 240.2 543.4 597.6 594.5 698.6 698.6 698.6
Announcement Date 5/12/20 4/27/21 4/27/22 4/26/23 4/24/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2020 2021 2022 2023 2024 2025 2026
Net sales 1 20,119 21,843 26,042 31,929 34,886 39,350 46,323
EBITDA 1 6,179 6,547 7,961 9,344 10,702 11,695 14,230
EBIT 1 - 3,802 4,864 5,679 6,443 7,100 9,106
Operating Margin - 17.41% 18.68% 17.79% 18.47% 18.04% 19.66%
Earnings before Tax (EBT) 1 5,169 4,692 4,844 5,936 6,208 7,387 9,430
Net income 1 4,121 4,049 3,958 4,644 5,100 5,724 7,181
Net margin 20.48% 18.54% 15.2% 14.54% 14.62% 14.55% 15.5%
EPS 2 10.35 10.11 9.820 11.51 12.69 13.74 17.51
Free Cash Flow 1 - 2,604 1,053 3,052 5,501 2,067 3,441
FCF margin - 11.92% 4.04% 9.56% 15.77% 5.25% 7.43%
FCF Conversion (EBITDA) - 39.77% 13.23% 32.66% 51.4% 17.67% 24.18%
FCF Conversion (Net income) - 64.31% 26.6% 65.72% 107.86% 36.11% 47.91%
Dividend per Share 2 - - 0.5000 0.5000 1.338 1.288 1.511
Announcement Date 5/12/20 4/27/21 4/27/22 4/26/23 4/24/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 5,845 6,586 5,945 6,102 6,414 7,581 6,445 7,681 7,859 9,944 8,081 9,144 8,964 10,276 7,790
EBITDA 1 1,762 2,107 1,650 1,774 2,034 2,503 1,728 2,165 2,466 3,141 2,119 2,704 2,676 3,122 2,570
EBIT 1 976 1,407 749 908 1,050 1,700 901 1,449 1,520 2,185 1,098 1,670 1,586 2,090 934.2
Operating Margin 16.7% 21.36% 12.6% 14.88% 16.37% 22.42% 13.98% 18.86% 19.34% 21.97% 13.59% 18.27% 17.69% 20.34% 11.99%
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 1,022 1,606 773 667 - 1,478 739 1,020 1,097 1,787 934 1,285 1,189 1,559 -
Net margin 17.49% 24.39% 13% 10.93% - 19.5% 11.47% 13.28% 13.96% 17.97% 11.56% 14.05% 13.26% 15.17% -
EPS 2 2.550 4.010 1.890 1.630 2.550 3.670 1.830 2.530 2.710 4.430 2.320 3.268 2.953 3.484 2.329
Dividend per Share 2 - - - - - 0.5000 0.1000 - - 0.5000 - - - 1.150 -
Announcement Date 1/20/21 4/27/21 7/20/21 10/20/21 1/19/22 4/27/22 7/20/22 10/19/22 1/23/23 4/26/23 7/26/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 2,497 2,601 7,808 9,350 9,103 13,710
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - 2,604 1,053 3,052 5,501 2,067 3,441
ROE (net income / shareholders' equity) 19.9% 16.2% 12.9% 13.4% 13.2% 12.2% 14%
ROA (Net income/ Total Assets) - 8.95% - 8.15% 8.66% 8.1% 8.9%
Assets 1 - 45,231 - 56,974 58,861 70,667 80,688
Book Value Per Share 2 54.40 70.50 82.30 90.10 101.0 119.0 134.0
Cash Flow per Share 2 - - - 20.40 23.20 22.80 26.60
Capex 1 - 4,465 4,755 5,066 4,920 9,025 7,436
Capex / Sales - 20.44% 18.26% 15.87% 14.1% 22.93% 16.05%
Announcement Date 5/12/20 4/27/21 4/27/22 4/26/23 4/24/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Syngene International Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
698.6 INR
Average target price
728.9 INR
Spread / Average Target
+4.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SYNGENE INTERNATIONAL LIMITED Stock Syngene International Limited
-0.41% 3.33B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SYNGENE Stock
  4. Financials Syngene International Limited